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In our opinion, available (cyto)genetic data do not sup-
port the conclusion of the authors, i.e., that PRDM16
haploinsufficiency causes cardiomyopathy in 1p36 dele-
tion syndrome. Furthermore, only 2/7 PRDM16 variants
claimed to be mutations were proven to be most likely
pathogenic (the two de novo truncating mutations).
Even though zebrafish and mouse data suggest a role
for PRDM16 in cardiac development (impaired prolifera-
tive capacity and contractile dysfunction with uncou-
pling of cardiomyocytes in zebrafish and ventricular
hypoplasia in mice), we are not convinced that this is
the cardiomyopathy-associated gene in 1p36 deletion
syndrome.Nicole de Leeuw1 and Gunnar Houge2,*
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Society of Human Genetics. All rights reserved.Reponse to de Leeuw and HougeTo the Editor: We thank Drs. de Leeuw and Houge for
their interest in our work, and we are grateful for the
opportunity to respond to their thoughtful comments.
However, we are concerned that they might have misread
some of the fundamental conclusions outlined in our
paper.1
We completely agree that haploinsufficiency of
PRDM16 (MIM 605557) is an unlikely or uncommon
cause of the cardiomyopathy in 1p36 deletion syndrome
(MIM 607872). In the context of substantial genomic
deletions, there are numerous potential mechanisms,
including contiguous or multigene effects, long-range reg-
ulatory effects, undetected rearrangements, and position
effects, to name but a few. It was for this very reason
that we used the initial inferences from existing data on
1p36 deletions simply as a means of generating a list of
candidate genes for the cardiomyopathy seen in this
syndrome. Indeed, we not only tested multiple genes
within the 1p36 deletion in our zebrafish model but
also chose to finally build a transgenic line expressing a
dominant-negative truncation mutant. For example, we
tested for mutations in SKI (MIM 164780) in non-
syndromic cardiomyopathy and even demonstrated the
interaction between PRDM16 and SKI in zebrafish with
the result that we did not exclude the effect of SKI, as
noted in the manuscript.
Most importantly, in our original paper, we went on to
obtain three additional independent lines of evidencebefore drawing any conclusions regarding the role of
PRDM16 in cardiomyopathy: (1) PRDM16 mutations in
nonsyndromic forms of left ventricular noncompaction
(MIM 604169), (2) a highly significant excess of deleterious
PRDM16 variants in adult dilated cardiomyopathy (DCM
[MIM 115200]), and (3) in vivo modeling data of several
PRDM16 variants in zebrafish. Together, all these data un-
equivocally support our assertion that mutations in
PRDM16 are a cause of human myocardial disease.
Although it remains conceivable, as we suggested, that
PRDM16 haploinsufficiency does contribute to the cardiac
or other phenotypes in some of the complex deletions
involving 1p36, we do not think that this is the most com-
mon mechanism for the reasons outlined in detail in our
original paper.
On the specific details that Drs. de Leeuw and Houge
outline in their letter, there are several important consider-
ations., 21. The genomic boundaries that we used for fine map-
ping of PRDM16 in 1p36 deletion syndrome were
based on the information that was publically avail-
able when the manuscript was submitted. Subse-
quent additions to the database have clarified the
genomic boundaries of two deletions. We apologize
that the genomic positions based on karyotype infor-
mation from the ECARUCA (European Cytogeneti-
cists Association Register of Unbalanced Chromo-
some Aberrations) cases were indicated as array
data in our submitted manuscript. The lack of an
obvious cardiomyopathy phenotype in other014
deletion mutants is difficult for us to comment on in
the absence of any phenotyping information in
ECARUCA or DECIPHER, but we would certainly
not expect all deletions to result in the same pheno-
type given the domain structure of PRDM16 and
own experimental data.
2. Mutations in PRDM16 in two distinct subsets of
cardiomyopathy offer additional support for the
role of PRDM16 in cardiomyopathy. Two missense
variants associated with DCM in our study are
found in dbSNP, but these were submitted by a
study in which exome sequencing of mainly
diseased individuals was performed,2 and so we did
not use these samples as controls. The five PRDM16
variants associated with DCM are extremely rare in
healthy individuals and fulfill objective criteria for
causality in DCM. The most relevant fact is that
the ‘‘variant burden’’ in individuals with DCM is
significantly higher than that in healthy controls
(p ¼ 0.006).
3. The PolyPhen-2 scores we used were those calculated
at the time of submission of our manuscript. These
in silico estimates are often useful as an indicator
of pathogenicity but are subject to significant change
as the weighting data accrue.
In summary, we agree that the directly defined genomic
boundaries of the 1p36 deletions should be used whenever
available, but the precise extent of individual deletions
associated with cardiomyopathy does not change the
resultant list of candidate genes. Our subsequent work
has outlined the multiple independent lines of evidence
supporting our assertion that mutations in PRDM16 cause
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